Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Vaccine Safety


Section Navigation
			
			CDC Home


Facebook
        Twitter
        LinkedIn
        Syndicate





VSD MMRV Safety Study										Related Pages
										Through use of CDC’s Vaccine Safety Datalink (VSD) Project’s rapid cycle analysis (RCA), scientists can detect adverse events in near real time so that the public can be informed quickly of any possible risks. VSD uses computerized data from managed care organizations, which gather data on vaccination, demographic information, and health outcomes of their patients (more than 8.8 million patients across the country each year).
As part of ongoing efforts to monitor the safety of vaccines, CDC used rapid cycle analysis to study the safety of the measles, mumps, rubella and varicella (MMRV) vaccine.
Methods
The study assessed risk for certain health outcomes, including seizures, within 42 days after vaccination among children aged 12-23 months who received MMRV vaccine. This is the age when the first dose is recommended for the MMRV vaccine as well as for the measles, mumps, rubella (MMR) and varicella vaccines. Investigators looked at how often certain outcomes occurred among children in the MMRV vaccine group compared with children who received MMR vaccine (many children also received varicella vaccine) mainly in the period before MMRV vaccine was available.
An increased risk for seizures of any cause was detected. The seizures were clustered around 7-10 days after vaccination in both groups (MMRV vaccine [1 shot] and MMR and varicella vaccines [2 separate shots] administered at the same visit).
Investigators reviewed the medical charts of children identified in the database as having had seizures 7-10 days after receiving an MMRV vaccine or MMR and varicella vaccines to distinguish febrile seizures from other kinds of seizures.
Investigators used statistical methods to compare rates of febrile seizures among children in two study groups: 1) children who received an MMRV vaccine during January 2006 -October 2008; and 2) children who received separate injections of MMR and varicella vaccines at the same visit during January 2000 -October 2008.Results
Findings from the VSD study of MMRV vaccine and the risk of febrile seizures are described below. Only children aged 12-23 months who received the first dose were studied. This information was presented at the June 2009 Advisory Committee on Immunization Practices (ACIP) meeting.
The study included 83,107 children who received their first dose of MMRV vaccine and 376,354 children who received their first doses of MMR and varicella vaccines administered at the same visit.
Of the children identified in the computerized data as having seizures 7-10 days after vaccination, about 90% were found to be febrile seizures after chart review.
The rates of febrile seizures that occurred 7-10 days after vaccination were 8.5 per 10,000 in the MMRV vaccine group compared with 4.2 per 10,000 in the MMR and varicella vaccine group. Thus, the risk was about 2 times higher in children who received the single shot vs. the two separate shots.
7-10 days after vaccination, about one additional febrile seizure would be expected to occur for every 2,300 children who receive an MMRV vaccine compared with children vaccinated with MMR and varicella vaccines at the same visit.
A similar percentage of children with febrile seizures in the MMRV vaccine group (30%) and the MMR and varicella vaccine group (29%) had a family history of seizures.Top of Page
							
					
						Page last reviewed:  June 29, 2020					Content source: 	Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Healthcare Quality Promotion (DHQP) homeVaccine Safety
Safety Information by Vaccineplus icon
Chickenpox (Varicella) Vaccines
COVID-19 Vaccines
Diphtheria, Tetanus, and Pertussis Vaccines
Haemophilus influenzae type b (Hib) Vaccines
Hepatitis A Vaccines
Hepatitis B Vaccines
Human Papillomavirus (HPV) Vaccineplus icon
Questions about HPV Vaccine Safety
Influenza (Flu) Vaccines
Measles, Mumps, Rubella (MMR) Vaccinesplus icon
MMR Safety Studies
Measles, Mumps, Rubella, Varicella (MMRV) Vaccinesplus icon
VSD MMRV Safety Study
MMRV Safety Studies
MMRV and Febrile Seizures
Meningococcal Vaccines
Mpox Vaccines
Pneumococcal Vaccines
Polio Vaccine
Respiratory Syncytial Virus (RSV) Vaccine
Rotavirus Vaccine
Shingles (Herpes Zoster) Vaccines
Smallpox Vaccines
Questions and Concernsplus icon
Adjuvants
Autismplus icon
CDC Statement: 2004 Pediatrics Paper on MMR and Autism
Fainting after Vaccination
Febrile Seizures
Guillain-Barre Syndrome
Multiple Vaccinations at Once
Sudden Infant Death Syndrome (SIDS)
Thimerosalplus icon
CDC Study (2010 ) on Thimerosal and Risk of Autism
Thimerosal FAQs
Related Scientific Articles
Infant and Environmental Exposures to Thimerosal 2007 Study
Timeline: Thimerosal in Vaccines
Vaccines During Pregnancy FAQs
FAQs about Vaccine Recalls
Historical Vaccine Safety Concernsplus icon
GBS and Menactra Vaccine FAQs
Gardasil Vaccine Recall (2013) FAQs
Hep B and Multiple Sclerosis FAQs
Hib Vaccine Recall (2007) Summary
Narcolepsy Following Pandemrix Influenza Vaccination in Europe
Information for Healthcare Providersplus icon
Talking to Patients About Vaccine Safety
Reporting Adverse Events
Resources for Healthcare Providers
Information for Parents and Caregiversplus icon
Vaccine Safety FAQs
Researchplus icon
Publications
Partner Reports on Vaccine Safety
ISO Scientific Agenda
Ensuring Safetyplus icon
Overview, History, and How It Works
Side Effects and Adverse Events
Vaccine Safety Monitoringplus icon
Vaccine Adverse Event Reporting System (VAERS)
CISAplus icon
CISA Resources for Healthcare Professionals
Evaluation
Clinical Research Studies
Historical Background 2001-12
Publications
Technical Reports
Vaccine Safety Datalink (VSD)plus icon
Accessing Data from Vaccine Safety Datalink
Data Sharing Guidelines
Vaccine Safety Datalink Publications
V-safe
V-safe Publications
Emergency Preparedness
Vaccine Safety Partners
About ISO To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue